[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostatic-cancer":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,82,106,136,164,197],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100312974","profiling-of-radiological-factors-in-treatment-and-outcomes-in-prostate-cancer-100312974",false,"NCT03354416","Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer","* INCLUSION CRITERIA:\n* Patients with an increased risk for prostate cancer (strong family history and\u002For germline mutation in DNA repair genes), or with a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.\n* Age greater than or equal to 18 years\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n-none","MALE","18 Years",{"count":18,"type":19},10000,"ESTIMATED","OBSERVATIONAL","Background:\n\nProstate cancer is one of the most common cancers for men in the U.S. There are some new ways to take pictures of the cancer. There are also new ways to use image-guided biopsy and therapy. These could help manage prostate cancer. Researchers want to study how imaging can provide a profile of prostate cancer. They want to collect data to make diagnosis and treatments better.\n\nObjectives:\n\nTo gather data about the radiological and clinical course of prostate cancer. To study imaging-based biomarkers of prostate cancer.\n\nEligibility:\n\nMen ages 18 and older with diagnosed or suspected prostate cancer\n\nDesign:\n\nParticipants will give permission for researchers to use their medical history and records. Their data will be reviewed, collected, and analyzed. These include results of their tests and scans.\n\nSponsoring Institution: National Cancer Institute",[23,24,25,26,27],"Prostatic Cancer","Prostatic Neoplams","Prostatic Hyperplasia","Prostate Cancer","Cancer Of Prostate",[29,30,31,32,33,34],"Imaging-Based Prognostic Markers","Multiparametric MRI (mpMRI)","Translation of Imaging into Treatment Decisions","Decision-Support System","Artificial Intelligence Research","Natural History","RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":39},"2018-02-26",{"date":43,"type":19},"2033-12-31",{"name":45,"class":46},"National Cancer Institute (NCI)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":16,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":58,"conditions":59,"keywords":68,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100453457","learn-learning-environment-for-artificial-intelligence-in-radiotherapy-new-technology-100453457","NCT05184790","LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology","LEARN","Inclusion Criteria:\n\n* Will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre.\n* Will receive CT planning, and a cone beam CT scan for at least one fraction of radiation therapy.\n* Will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. As intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites.\n* Provides written informed consent.\n\nExclusion Criteria:\n\n* Less than 18 years of age","ALL",{"count":57,"type":19},300,"This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance.\n\nRoutinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.",[60,61,23,62,63,64,65,66,67],"Arrhythmias, Cardiac","Breast Cancer","Brain Cancer","Kidney Cancer","Head and Neck Cancer","Liver Cancer","Pancreatic Cancer","Spinal Neoplasm",[69,70],"Radiation Therapy","markerless tracking","2026-05-18",{"date":73,"type":39},"2026-05-19",{"date":75,"type":39},"2023-02-28",{"date":77,"type":19},"2028-01-31",{"name":79,"class":80},"University of Sydney","OTHER",4,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":15,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":47},"100497233","high-dose-brachytherapy-boost-with-stereostatic-body-radiation-therapy-to-intermediate-or-higher-risk-prostate-cancer-100497233","NCT05754580","High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer","High-dose Rate (HDR) Brachytherapy Boost With Stereostatic Body Radiation Therapy (SBRT) to Prostate and Pelvic Nodes for the Initial Treatment of Unfavorable Intermediate or Higher Risk Prostate Cancer","Inclusion Criteria:\n\n1. Histopathologically proven diagnosis of local unfavorable intermediate or higher risk prostate cancer as defined by NCCN risk group criteria. Biopsies will be confirmed by UNMC pathology review if collected outside our institution.\n2. No prior definitive treatment or intervention received.\n3. Life expectancy of more than 10 years as estimated by the treating physician.\n4. Negative evaluation lymph node involvement or distant metastatic disease on abdominopelvic CT, prostate MRI, and\u002For PSMA PET.\n5. Negative evaluation of osseous metastatic disease via bone scan or PSMA PET scan.\n6. Greater than or equal to 15% nodal involvement risk predicated on publicly available MSKCC pre-prostatectomy nomogram.\n7. Karnofsky performance status ≥ 80 within 30 days prior to registration.\n8. Age ≥ 19 years.\n9. Clinically determined to be a candidate for HDR brachytherapy.\n10. Patient must be able to provide study-specific informed consent prior to study entry.\n\nExclusion Criteria:\n\n1. American Urological Association Urinary Symptom Score (AUA score) ≥ 15.\n2. Large prostate volume relative to pelvic arch width that can hinder proper placement of applicator insertion. To be done by MRI, TRUS, and\u002For physical exam for size, by CT A\u002FP or MRI for arch interference. Specifically, prostates must be no greater than 75 cc in size as decerned by MRI, TRUS, or physical exam. Potential for pubic arch interference will be decerned by the treating radiation oncologist based on MRI and\u002For CT imaging.\n3. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.\n4. Relative or absolute contraindications to radiation therapy as determined by the treating physician. These include, but not limited to, inflammatory bowel disease, connective tissue disorders (systemic lupus erythematosus, scleroderma, etc.), genetic disorders that risk increase sensitivity to radiation therapy.\n5. Medical conditions that, in the opinion of the investigator could compromise patient safety.\n6. Prior invasive malignancy other than prostate cancer (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year.\n7. History of rectal surgeries.\n8. Recent major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to registration.\n9. History of Urolift.\n10. Contraindications to general anesthesia.\n11. Preexisting rectal fistula.","19 Years",{"count":91,"type":19},53,"INTERVENTIONAL",[94],"NA","The objective of this phase I\u002FII trial is to prospectively evaluate the toxicity and therapeutic efficacy of Stereostatic Body Radiation Therapy (SBRT) to prostate and pelvic lymph nodes in combination with high-dose-rate (HDR) brachytherapy to the prostate in patients with localized unfavorable-intermediate risk or higher disease.",[23],"2025-11-03",{"date":99,"type":39},"2025-11-05",{"date":101,"type":39},"2023-08-29",{"date":103,"type":19},"2027-10",{"name":105,"class":80},"University of Nebraska",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":55,"minAge":16,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":92,"phases":116,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":47},"100496186","phase-1-a-study-of-hansoh-hs-10502-in-patients-with-advanced-solid-tumors-100496186","NCT05740956","A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Males or females aged 18 - 75 years (inclusive).\n2. Having at least one target lesion per the RECIST v1.1.\n3. For the phase Ia Cohort A: advanced solid tumor carrying HRR gene mutation with failure or intolerance or not available to the currently available Standard of care (SoC).\n4. For the phase Ib study:\n\n   Cohort B: patients with HRD positive recurrent ovarian cancer with failure or intolerance or not available to SoC Cohort C: patients with HRR gene mutation advanced Human epidermal growth factor receptor 2 (HER2)-negative breast cancer with failure or intolerance or not available to SoC Cohort D: patients with HRR gene mutation advanced pancreatic cancer with failure or intolerance or not available to SoC Cohort E: patients with HRR gene mutation mCRPC with failure or intolerance or not available to SoC Cohort F: patients with HRR gene mutation colorectal cancer with failure or intolerance or not available to SoC Cohort G: patients with other HRR gene mutation or HRD positive advanced solid tumors with failure or intolerance or not available to SoC\n5. Eastern cooperative oncology group (ECOG) performance status was 0-1.\n6. Minimum life expectancy \\> 12 weeks.\n7. Females should be using adequate contraceptive measures and should not be breastfeeding Males should be using adequate contraceptive measures.\n8. Have signed Informed Consent Form.\n\nExclusion Criteria:\n\n1. Received or are receiving the following treatments:\n\n   1. Previous or current treatment with two or more Poly(ADP-ribose) polymerase (PARP) inhibitors.\n   2. Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of study treatment.\n   3. Cytotoxic chemotherapeutic drugs, investigational drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment; Nitrosourea or Mitomycin C within 6 weeks prior to the first dose of study treatment.\n   4. Local radiotherapy within 2 weeks prior to the first dose of study treatment; more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment.\n   5. Presence of pleural effusion\u002Fascites requiring clinical intervention; presence of pericardial effusion.\n   6. Major surgery within 4 weeks prior to the first dose of study treatment.\n2. Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.\n3. History of other primary malignancies.\n4. Known and untreated, or active central nervous system metastases.\n5. Inadequate bone marrow reserve or hepatic and renal functions.\n6. Myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), or with features suggestive of MDS or AML.\n7. Severe, uncontrolled or active cardiovascular disorders.\n8. Diabetic ketoacidosis or hyperosmolar hyperglycemic state within 6 months prior to the first dose of study treatment; glycosylated hemoglobin ≥ 7.5%.\n9. Serious or poorly controlled hypertension.\n10. Any life-threatening hemorrhagic event or events requiring blood transfusion within 120 days prior to the first dose of study treatment. Clinically significant hemorrhagic symptoms or obvious hemorrhagic tendency.\n11. Serious infection within 4 weeks prior to the first dose of study treatment, or presence of uncontrollable active infection in the screening period.\n12. Having serious neurological or mental disorders.\n13. A history of hypersensitivity to any of the active or inactive ingredients of HS-10502 or drugs with a similar chemical structure to HS-10502 or in the same class as HS-10502.\n14. Patients who may have poor compliance with the procedures and requirements of the study, as judged by the investigator.\n15. Patients with any condition that jeopardizes the safety of the patient or interferes with the assessment of the study, as judged by the investigator.","75 Years",{"count":115,"type":19},318,[117],"PHASE1","HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.",[120,61,66,23,121],"Ovarian Cancer","Colorectal Cancer",[123,124,120,61,125],"Poly(ADP-ribose) polymerase-1 inhibitor","HS-10502","Prostate Cancer, Colorectal Cancer","2025-06-02",{"date":128,"type":39},"2025-06-05",{"date":130,"type":39},"2023-06-09",{"date":132,"type":19},"2026-10-01",{"name":134,"class":135},"Jiangsu Hansoh Pharmaceutical Co., Ltd.","INDUSTRY",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":55,"minAge":4,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":92,"phases":145,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100580359","phase-2-cleaning-the-biopsy-needle-in-trus-bx-100580359","NCT06836271","Cleaning the Biopsy Needle in TRUS Bx","The Effect of Cleaning the Biopsy Needle With Isopropyl Alcohol, Povidone Iodine and Formalin Before Transrectal Ultrasonography-guided Prostate Biopsy on Procedure-related Infective Complications","Inclusion Criteria:\n\n* Oriented-coopere patients\n* Patients without active urinary tract infection - Patients without active urinary tract infection\n* Patients without bleeding diathesis\n* Patients who accept the study\n\nExclusion Criteria:\n\n* Patients with active urinary tract infection\n\n  * Patients with bleeding diathesis\n  * Patients with sonal or cystofix\n  * Patients with a history of previous prostate surgery",{"count":144,"type":19},200,[146],"PHASE2","Prostate cancer(PCa) is the second most common cancer diagnosed in men. Clinical suspicion of PCa is mentioned in patients with digital rectal examination findings and elevated serum PSA. Despite all the advances in radiological imaging methods, the gold standard method in the diagnosis of the disease is systematic prostate biopsy performed under the guidance of transrectal ultrasonography, which is an invasive procedure.\n\nIn TRUS-guided transrectal prostate biopsy, bacteriuria may develop as a result of the rectum flora being injected into the urinary system through a biopsy needle. Infective complications may be encountered as a result of this contamination. Infective complications can present with conditions ranging from asymptomatic bacteriuria to sepsis.\n\nA study has shown that disinfection of the biopsy needle with isopropyl alcohol reduces sepsis due to prostate biopsy compared to the standard procedure. In another study, disinfection of the biopsy needle tip with formalin was found to be associated with a decrease in infectious complications after transrectal prostate biopsy.\n\nIn this study, investigators aimed to conduct a prospective study comparing Transrectal Ultrasonography-guided Prostate Biopsy cases, in which the biopsy needle was cleaned with isopropyl alcohol, povidone iodine and formalin, and standard biopsy patients in terms of infectious complications.",[23],[150,151,152,153],"Prostatic Neoplasms","Needle washing","Prostate biopsy","Sepsis","NOT_YET_RECRUITING","2025-02-14",{"date":157,"type":39},"2025-02-20",{"date":159,"type":19},"2025-03-01",{"date":161,"type":19},"2025-06-30",{"name":163,"class":80},"Hitit University",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":55,"minAge":16,"maxAge":113,"enrollmentInfo":171,"targetDuration":4,"studyType":92,"phases":173,"briefSummary":174,"conditions":175,"keywords":183,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":47},"100579047","phase-1-phase-iii-clinical-study-to-evaluate-vb15010-tablets-in-patients-with-advanced-solid-tumors-100579047","NCT06819215","Phase I\u002FII Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors","Phase I\u002FII Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Preliminary Efficacy of VB15010 Tablets In Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Age ≥ 18 at the time of screening;\n* Histological or cytological confirmation of advanced malignancy ;\n* Progressive cancer at the time of study entry;\n* Adequate organ and marrow function as defined by the protocol;\n* Homologous recombination repair gene mutation.\n\nExclusion Criteria:\n\n* Major surgery within 4 weeks of the first dose of study treatment.\n* Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of \\>10mg prednisone\u002Fday or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.\n* Patients with myelodysplastic syndrome\u002Facute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)\u002Facute myeloid leukaemia (AML).",{"count":172,"type":19},188,[117,146],"This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.",[176,177,178,179,180,181,23,66,61,182,121],"Cancer","Neoplasms","Neoplasms, Breast","Tumor","PARP","Ovarian Neoplasms","Biliary Cancer",[184,180,185,23,186,187,182],"VB15010","Ovarian cancer","Pancreatic cancer","Breast cancer","2025-02-04",{"date":190,"type":39},"2025-02-11",{"date":192,"type":39},"2024-10-30",{"date":194,"type":19},"2026-03-30",{"name":196,"class":135},"Zhejiang Yangli Pharmaceutical Technology Co., Ltd.",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":92,"phases":207,"briefSummary":208,"conditions":209,"keywords":210,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":47},"100549878","contribution-of-the-veriton-ct-camera-in-prostate-bone-radiostereotaxy-100549878","NCT06439784","Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy","Contribution of 99mTc-HDP Whole-body SPECT\u002FCT Imaging by VERITON-CT CZT Camera in Stereotactic Radiotherapy Treatment of Bone Metastases of Prostate Cancer","VERIOS","Inclusion Criteria:\n\n* Age ≥ 18 years,\n* Good general health WHO ≤ 1\n* Informed and signed consent prior to any specific study procedure.\n* Patient affiliated to the social security system\n* Bone metastases from prostate cancer\n* Indication for bone stereotactic radiotherapy\n\nExclusion Criteria:\n\n* Presence of active cancer in the previous three years\n* Protected adults (under guardianship or curatorship)\n* Unable to undergo medical monitoring for geographical, social or psychological reasons\n* Unable to decubitus (orthopnea, etc.),\n* Hypersensitivity to HDP or to one of the excipients of the radiopharmaceutical.\n* History of radiotherapy of the volume to be treated by stereotaxy.",{"count":206,"type":19},30,[94],"Stereotactic radiotherapy enables bone metastases to be treated with highly precise irradiation beams, enabling small targets to be irradiated. Planning requires the use of cross-sectional imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). Bone scintigraphy with Tc99m-labelled biphosphonates (T1\u002F2=6h) is indicated in the extension assessment of prostate cancers. Thanks to the advent of single-photon emission computed tomography (SPECT) based on CZT detectors; whole-body SPECT is now compatible with clinical constraints. We propose to study the value of using whole-body SPECT for planning stereotactic radiotherapy of metastatic prostate cancer. This is a prospective, single-center, non-randomized study involving 30 patients. Patients will benefit from routine examinations (CT scan, MRI) including a bone SPECT\u002FCT in treatment position performed on the VERITON-CT (Spectrum Dynamics, Haifa, Israel). Planning based on whole-body SPECT images will be carried out remotely from the patient's point of care. The examination will be interpreted by the nuclear physician, and planning will be based on the dosimetric CT scanner, as in standard management. Virtual replanning will be carried out at distance from treatment, incorporating SPECT imaging. Treatment plans with and without SPECT will be compared quantitatively and qualitatively. The feasibility of SPECT imaging in the treatment position will be assessed, enabling lesion location imaging and dosimetric scanning to be performed in a single examination. All therapeutic management and clinical follow-up will be carried out as part of routine care.",[23],[211,212,213],"whole body SPECT\u002FCT","bone scintigraphy","stereotaxic bone radiation therapy","2024-05-28",{"date":216,"type":39},"2024-06-03",{"date":218,"type":19},"2024-06-15",{"date":220,"type":19},"2027-06-15",{"name":222,"class":80},"Centre Henri Becquerel"]